Ultragenyx nears $50M Series A for its Alzheimer's gene therapy spinout: #JPM24

Kyle LaHucik

Senior Reporter

SAN FRANCISCO — Ultragenyx, the commercial-stage California biotech working on ultra-rare diseases, is finishing up a $50 million Series A fundraise for its Alzheimer’s gene …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ultragenyx nears $50M Series A for its Alzheimer's gene therapy spinout: #JPM24

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ul­tragenyx nears $50M Se­ries A for its Alzheimer's gene ther­a­py spin­out: #JPM24

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ultragenyx nears $50M Series A for its Alzheimer's gene therapy spinout: #JPM24